Abstract
Myeloproliferative neoplasms (MPNs) are clonal malignant diseases that represent a group of conditions including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). The JAK2-V617F mutation is prevalent in almost all patients with MPNs and has become a valuable biomarker for diagnosis of MPNs. A different allele burden in these entities has long been noticed. The aim of our study was to assess the JAK2 allele burden in our JAK2V617F positive cases and its association with phenotype if any and to select a simple, sensitive assay for use in our clinical molecular diagnostic laboratory. Methodologies reported in this literature include amplification refractory mutation system–polymerase chain reaction (ARMS-PCR) and real-time quantitative polymerase chain reaction (RQ-PCR). We analyzed 174 cases by RQ-PCR for the quantification of JAK2V617F were initially screened by ARMS-PCR. We found that V617F allele burden in the entire population of patients was 73 % ranging from 0.97 to 95 %. The median V617F allele burden in PV patients was 40 %, MF was 95 %, and ET was 25 %. ARMS-PCR and RQ-PCR were proven to be sensitive since ARMS-PCR is a qualitative method; it can be used to screen JAK2V617F mutation and RQ-PCR was used to quantify the V617F cells. Our study suggests that JAK2V617F positivity is associated with MPNs, and its allele burden is an excellent diagnostic marker for disease subtypes, prognosis, disease phenotype and complication, and evolution. The data indicates that ARMS-PCR is simple and can be easily performed for the primary screening of JAK2V617F mutation, and RQ-PCR is sensitive enough to detect low mutant allele levels (>10 %), specific enough not to produce false positive results, and can be performed for the JAK2V617F allele burden quantification.
Similar content being viewed by others
References
Levine LR, Gilliland DG (2008) Myeloproliferative disorders. Blood 112:2190–2197
Spivak JL (2004) The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 41:1–5
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061
Jamieson CH, Gotlib J, Durocher JA (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 103:6224–6229
James C, Ugo V, LeCouedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434:1144–11486
Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790
Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397
Steensma DP, Dewald GW, Lasho TL et al (2005) The JAK2V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207–1209
Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945–1953
Denys B, El Housni H, Nollet F, Verhasselt B, Philippe J (2010) A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide. J Mol Diagn 12(4):512–519
Huijsmans CJ, Poodt J, Savelkoul PH, Hermans MH (2011) Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. J Mol Diagn 13(5):558–564
Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7):1299–1307
Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14–22
Steensma DP (2006) JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8(4):397–411, quiz 526
Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B et al (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94:38–45
Dino V, Enrico C, Matteis G, Franchini M, Elisabetta B, Benati M, Pietro Soler G, Achille A, Giulia Q, Giovanni Pizzolo (2009) Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus 7:204–209. doi:10.2450/2009.0070-08
Milena C, Lisa W, Robert Hawley C, Richard Zarbo J, Dhananjay C (2009) Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory. Evaluation of screening and quantitation methods. Am J Clin Pathol 132:713–721
Buors C, Douet N, Morel F, Lecucq L, Cassinat B, Ugo V (2012) Blood Cancer J 2:e66. doi:10.1038/bcj.2012.11
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase A, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou E, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NCP (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168
Tefferi A, Skoda R, Vardiman JW (2009) Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 6(11):627–637
Konstantou JK, Iliadi AC, Ioannou PC, Christopoulos TK, Anagnostopoulos NI, Kanavakis E et al (2010) Visual screening for JAK2V617F mutation by a disposable dipstick. Anal Bioanal Chem 397(5):1911–1916
Passamonti F, Rumi E et al (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94(1):7–10
Veneri D, Capuzzo E et al (2009) Comparison of JAK2V617F assessment employing different molecular diagnostic techniques. Blood Transf 7:204–209
Korger N, Badbaran A, Holler E et al (2007) Monitoring of the JAK2V617F mutation by highly sensitive quantitative real-time PCR after allogenic stem cell transplantation in patients with myelofibrosis. Blood 109:1316–1321
Jones AV, Silver RT, Waghorn K et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107:3339–3341
Campbell PJ, Baxter EJ, Beer PA et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548–3555
Vannuchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21:1952–1959
Vannuchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846
Walz C, Cross NPC, Van Etten RA et al (2008) Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22:1320–1334
Morgan KJ, Gilliland DG (2008) A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 59:213–222
Chen Q, Lu P, Jones A et al (2007) Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. JMD 9:2
Author information
Authors and Affiliations
Corresponding author
Additional information
This work is funded by Kuwait Foundation for the Advancement of Sciences (KFAS grant number: 2008130204).
Rights and permissions
About this article
Cite this article
Alshemmari, S.H., Rajaan, R., Ameen, R. et al. JAK2V617F allele burden in patients with myeloproliferative neoplasms. Ann Hematol 93, 791–796 (2014). https://doi.org/10.1007/s00277-013-1988-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-013-1988-6